Drug profile · INN
etravirine
INTELENCE
etravirine (INTELENCE) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with Janssen-Cilag Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — etravirine
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
etravirine (INTELENCE) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with Janssen-Cilag Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Primary target: Human immunodeficiency virus type 1 reverse transcriptase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is etravirine?
etravirine (INTELENCE) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with Janssen-Cilag Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for etravirine?
INTELENCE is a marketed brand name for etravirine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of etravirine?
etravirine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.